Chemomab Therapeutics Ltd.
CMMB
$2.49
-$0.04-1.58%
NASDAQ
| 06/30/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -51.79% | -62.96% | -68.33% | 38.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -42.11% | -49.18% | -53.13% | 101.79% |
| Operating Income | -- | 42.11% | 49.18% | 53.13% | -101.79% |
| Income Before Tax | -- | 42.43% | 50.46% | 54.40% | -100.33% |
| Income Tax Expenses | -- | -- | -- | -184.62% | -- |
| Earnings from Continuing Operations | -- | 42.43% | 50.48% | 54.66% | -97.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | 42.43% | 50.48% | 54.66% | -97.10% |
| EBIT | -- | 42.11% | 49.18% | 53.13% | -101.79% |
| EBITDA | -- | 42.19% | 49.28% | 53.23% | -101.91% |
| EPS Basic | -- | 58.38% | 61.89% | 61.59% | -97.42% |
| Normalized Basic EPS | -- | 76.77% | 76.94% | 82.47% | -100.60% |
| EPS Diluted | -- | 58.38% | 61.89% | 61.59% | -97.42% |
| Normalized Diluted EPS | -- | 76.77% | 76.94% | 82.47% | -100.60% |
| Average Basic Shares Outstanding | -- | 38.18% | 30.60% | 18.98% | 0.32% |
| Average Diluted Shares Outstanding | -- | 38.20% | 30.52% | 18.99% | 0.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |